Weekend high-dosage prednisone
A new option for treatment of Duchenne muscular dystrophy
Get full access to this article
View all available purchase options and get full access to this article.
REFERENCES
1.
Moxley RT, Ashwal S, Pandya S, et al. Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2005;64:13–20.
2.
Balaban B, Matthews DJ, Clayton GH, Carry T. Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: long-term effect. Am J Phys Med Rehabil 2005;84:843–850.
3.
Biggar WD, Harris VA, Eliasoph L, Alman B. Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscul Disord 2006;16:249–255.
4.
King WM, Ruttencutter R, Nagaraja HN, et al. Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy. Neurology 2007;68:1607–1613.
5.
Houde S, Filiatrault M, Fournier A, et al. Deflazacort use in Duchenne muscular dystrophy: an 8-year follow-up. Pediatr Neurol 2008;38:200–206.
6.
Moxley RT, Pandya S, Ciafaloni E, Fox DJ, Campbell K. Change in natural history of Duchenne muscular dystrophy with long-term corticosteroid treatment: implications for management. J Child Neurol 2010;25:1116–1129.
7.
Escolar DM, Hache LP, Clemens PA, et al. Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy. Neurology 2011;77:444–452.
8.
Connolly AM, Schierbecker J, Renna R, Florence J. High dose weekly oral prednisone improves strength in boys with Duchenne muscular dystrophy. Neuromuscul Disord 2002;12:917–925.
Information & Authors
Information
Published In
Copyright
Copyright © 2011 by AAN Enterprises, Inc.
Publication History
Published online: July 13, 2011
Published in issue: August 2, 2011
Disclosure
Dr. Moxley receives research support from the NIH (NCRR/NIAMS) and NINDS, which supports the Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center; has served on scientific advisory boards for the NIH and the CDC; and has served as a consultant for Insmed, Inc. Dr. Pandya serves as a consultant for Acceleron Pharma and Shire plc and receives research support from the NIH and the CDC.
Authors
Metrics & Citations
Metrics
Citation information is sourced from Crossref Cited-by service.
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
Cited By
- Development of a New Self-Reporting Instrument Measuring Benefits and Side Effects of Corticosteroids in Duchenne Muscular Dystrophy: Report from a Pilot Study, Journal of Neuromuscular Diseases, 4, 3, (217-236), (2017).https://doi.org/10.3233/JND-170223
- What’s Next in the Field of Bone Health in Pediatrics? Research Considerations, Bone Health Assessment in Pediatrics, (285-313), (2016).https://doi.org/10.1007/978-3-319-30412-0_13
- Evaluation of Fracture Without Known Trauma: Use of DXA in Differential Diagnosis, Bone Health Assessment in Pediatrics, (267-283), (2016).https://doi.org/10.1007/978-3-319-30412-0_12
- Transplantation of human umbilical cord-derived mesenchymal stems cells for the treatment of Becker muscular dystrophy in affected pedigree members, International Journal of Molecular Medicine, 35, 4, (1051-1057), (2015).https://doi.org/10.3892/ijmm.2015.2084
- Clinical Management of Dystrophinopathies, Neuromuscular Disorders of Infancy, Childhood, and Adolescence, (593-619), (2015).https://doi.org/10.1016/B978-0-12-417044-5.00031-7
- Newborn bloodspot screening for Duchenne Muscular Dystrophy: 21 years experience in Wales (UK), European Journal of Human Genetics, 21, 10, (1049-1053), (2013).https://doi.org/10.1038/ejhg.2012.301
- Osteoporosis in Childhood and Adolescence, Osteoporosis, (1037-1086), (2013).https://doi.org/10.1016/B978-0-12-415853-5.00043-1
- Evidence‐based path to newborn screening for duchenne muscular dystrophy, Annals of Neurology, 71, 3, (304-313), (2012).https://doi.org/10.1002/ana.23528
Loading...
View Options
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.
If you need immediate support or to place an order, please call or email customer service:
- 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
- 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
- [email protected]
We appreciate your patience during this time and apologize for any inconvenience.